Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease (FABRyCar)

Núcleo de Apoio à Investigação Clínica - FMUP

Status: Not yet enrolling

Conditions: Fabry Disease

Treatments: Procedure: PET scan of 68Ga-FAPI

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07351136

FABRyCar

Details and patient eligibility

About

In this work, we address the understanding of the signaling pathways involved in cardiac remodeling in human SCD through molecular imaging analysis with a fibrosis marker. Furthermore, we emphasize characterizing the cardiac remodeling process by analyzing proteomic data from SCD myocardial biopsies and by analyzing the profile of microRNAs associated with hypertrophic cardiomyopathy and their diagnostic and prognostic value.

Full description

The objective of this work is to explore the cardiac PET/CT imaging characteristics of cardiac fibroblast activation protein inhibitor (FAPI) and its relationship with the risk of sudden cardiac death (SCD) associated with myocardial fibrosis in SCD.

We also aim to deepen our understanding of the signaling pathways involved in SCD cardiac remodeling by comparing imaging data with proteomic and microRNA data.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, over 18 years of age;
• Diagnosis of Fabry disease

Exclusion criteria

• Refusal to participate in the study

Trial design

20 participants in 1 patient group

adults with Fabry disease

Treatment:

Procedure: PET scan of 68Ga-FAPI